# EDGAR Filing Document

**Accession Number:** 0002094574
**File Stem:** 0001193125-25-260850
**Filing Date:** 2025-10
**Character Count:** 8544
**Document Hash:** 58d37ed536b8ce6fef55f90009d860d1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-260850.hdr.sgml**: 20251031

**ACCESSION NUMBER**: 0001193125-25-260850

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251017

**FILED AS OF DATE**: 20251031

**DATE AS OF CHANGE**: 20251031

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Keenan David Paul
- **CENTRAL INDEX KEY:** 0002094574

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-21392
- **FILM NUMBER:** 251440900

**MAIL ADDRESS:**
- **STREET 1:** 440 US-22, SUITE 300
- **CITY:** BRIDGEWATER
- **STATE:** NJ
- **ZIP:** 08807
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AMARIN CORP PLC\UK
- **CENTRAL INDEX KEY:** 0000897448
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** SPACES SOUTH DOCKLANDS, BLOCK C
- **STREET 2:** 77 SIR JOHN ROGERSON'S QUAY
- **CITY:** DUBLIN 2
- **PROVINCE COUNTRY:** L2
- **BUSINESS PHONE:** 353 1 6699 020

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** SPACES SOUTH DOCKLANDS, BLOCK C
- **STREET 2:** 77 SIR JOHN ROGERSON'S QUAY
- **CITY:** DUBLIN 2
- **PROVINCE COUNTRY:** L2

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMARIN PHARMACEUTICALS PLC
- **DATE OF NAME CHANGE:** 20000201

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ETHICAL HOLDINGS PLC
- **DATE OF NAME CHANGE:** 19930322

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Keenan David Paul<br><sub>(Last) (First) (Middle)</sub><br>C/O AMARIN PHARMA, INC.<br>440 US HIGHWAY 22<br><sub>(Street)</sub><br>BRIDGEWATER, NJ 08807<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>AMARIN CORP PLC\UK [ AMRN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-10-17 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_EVP, Chief Operating Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| American Depositary Share<sup>(1)</sup> | 7950 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Restricted Stock Units<sup>(2)</sup> | <sup>(3)</sup> | <sup>(4)</sup> | American Depositary Share<sup>(1)</sup> | 6740 | $0 | D |  |
| Restricted Stock Units<sup>(2)</sup> | <sup>(5)</sup> | <sup>(4)</sup> | American Depositary Share<sup>(1)</sup> | 5800 | $0 | D |  |
| Restricted Stock Units<sup>(2)</sup> | <sup>(6)</sup> | <sup>(4)</sup> | American Depositary Share<sup>(1)</sup> | 7376 | $0 | D |  |
| Stock Option (Right to Buy) | <sup>(7)</sup> | 2035-01-10 | American Depositary Share<sup>(1)</sup> | 33193 | 12.40<sup>(8)</sup> | D |  |
| Stock Option (Right to Buy) | <sup>(9)</sup> | 2034-02-01 | American Depositary Share<sup>(1)</sup> | 20900 | 24.20<sup>(8)</sup> | D |  |
| Stock Option (Right to Buy) | <sup>(10)</sup> | 2033-02-21 | American Depositary Share<sup>(1)</sup> | 13480 | 36.00<sup>(8)</sup> | D |  |
| Stock Option (Right to Buy) | <sup>(11)</sup> | 2032-06-01 | American Depositary Share<sup>(1)</sup> | 5000 | 29.00<sup>(8)</sup> | D |  |

---

### Footnotes:

(1) Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 3 reflect the ADS Ratio Change.

(2) Each RSU represents a contingent right to receive twenty Ordinary Shares or cash in lieu thereof at the Issuer's discretion.

(3) On February 21, 2023, the Reporting Person was granted 6,740 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs vest in three equal installments on each of January 31, 2024, January 31, 2025 and January 31, 2026.

(4) Not applicable.

(5) On February 1, 2024, the Reporting Person was granted 5,800 RSUs under the Plan. These RSUs vest in three equal installments on each of January 31, 2025, January 31, 2026 and January 31, 2027.

(6) On January 10, 2025, the Reporting Person was granted 7,376 RSUs under the Plan. These RSUs vest over eighteen months, with 50% to vest on the first anniversary of the grant date and the remaining balance to vest eighteen months after grant date.

(7) On January 10, 2025, the Reporting Person was granted an option to purchase 33,193 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable over eighteen months, with 50% to vest on the first anniversary of the grant date and the remaining balance to vest eighteen months after grant date.

(8) Grant price is set at the higher of (1) our nominal par value of 50 pence per share, as converted on date of grant, for which our Plan dictates under United Kingdom law, or (2) fair market value of stock price on the NASDAQ at close of business day.

(9) On February 1, 2024, the Reporting Person was granted an option to purchase 20,900 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable over three years, with 33% to vest on the first anniversary of the grant date and the balance to vest ratably over the subsequent 8 calendar quarters on the last day of each April, July, October and January.

(10) On February 21, 2023, the Reporting Person was granted an option to purchase 13,480 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable over three years, with 33% to vest on the first anniversary of the grant date and the balance to vest ratably over the subsequent 8 calendar quarters on the last day of each April, July, October and January.

(11) On June 1, 2022, the Reporting Person was granted an option to purchase 5,000 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable over four years, with 25% to vest on the first anniversary of the grant date and the balance to vest ratably over the subsequent 12 calendar quarters on the last day of each April, July, October and January.

**Signature:** /s/ Jonathan Provoost, by power of attorney  
**Date:** 2025-10-31

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**